Andras A. Heczey, MD


  • Texas Medical Center



Phone: 832-822-4242
Fax: 832-825-1453

Contact Information

1102 Bates Ave.
Suite 1760.10
Houston, TX 77030
United States

Director, Liver Tumor Program
Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine


School Education Degree Year
Baylor College of Medicine fellowship Pediatric Hematology Oncology 2012
Children's Hospital of Los Angeles residency Pediatrics 2009
Semmelweis Medical University, Hungary residency Infectious Disease 2006
Semmelweis University medical school Doctor of Medicine 2002


Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology and Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT).

Board Certifications
General Pediatrics, American Board of Pediatrics
Pediatric Hematology and Oncology, American Board of Pediatrics

News Articles:

New Approach for Liver Cancer 


Organization Name Role
American Society of Cell and Gene Therapy Member
American Society of Clinical Oncology (ASCO) Member
American Society of Pediatric Hematology and Oncology (ASPHO) Member
Children's Oncology Group (COG) Member

Research Statement

His research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack cancer cells.

Dr. Heczey has studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells genetically modified to attack neuroblastoma, he is working on moving this approach from bench-to-bedside in a form of a Phase 1/2a clinical trial.

As the Director of the Liver Tumor Center, Dr. Heczey has developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically engineered T lymphocytes and he is currently optimizing this strategy for a smooth transition into the clinic.

Dr. Heczey’s research is focused on redirecting the immune system to attack and kill cancer cells by using genetically engineered T cells and Natural Killer T cells. He has developed bispecific T cell engagers and chimeric antigen receptors, which when expressed in T cells, specifically target hepatoblastoma and hepatocellular carcinoma. His goal is to cure all patients with liver cancers by translating these methods from the laboratory setting to the patient care clinic.


Good Student and Good Athlete of the Republic of Hungary, 2000. From the Ministry of Education of Hungary

Associates and Affiliates Award of the Children's Hospital of Los Angeles, 2009, For scientific knowledge, clinical judgment and excellence in human relations

Tumor Board Award, 2010, Texas Children's Cancer and Hematology Centers

Chief Fellow, 2011-2012, Texas Children's Cancer and Hematology Centers

Fellows’ Excellence in Education Award, 2015, Texas Children's Cancer and Hematology Centers

Faculty Recognition Award, 2017, Texas Children’s Cancer and Hematology Centers 

Biotherapeutics Award, 2017, Alex's Lemonade Stand Foundation 

Related Videos

  • Embedded thumbnail for TARE procedure available for pediatric liver cancer patients at Texas Children's Hospital
    TARE procedure available for pediatric liver cancer patients at Texas Children's Hospital
  • Embedded thumbnail for Liver Tumor Program at Texas Children's Cancer Center
    Liver Tumor Program at Texas Children's Cancer Center